Astellas’ five-year plan includes chasing record sales and cost cutsnews2026-05-26T11:10:04+00:00May 26th, 2026|Endpoints News|
FDA clears Gilead’s hepatitis D drug, four years after prior rejectionnews2026-05-22T18:35:28+00:00May 22nd, 2026|Endpoints News|
AstraZeneca wins EU backing for breast cancer drug, splitting with FDA panel news2026-05-22T16:47:59+00:00May 22nd, 2026|Endpoints News|
Novartis says Avidity’s science could apply beyond muscular dystrophiesnews2026-05-22T13:00:54+00:00May 22nd, 2026|Endpoints News|
Ibrance heirs, Gilead’s Tubulis data and more at #ASCO26news2026-05-22T11:05:27+00:00May 22nd, 2026|Endpoints News|
#ASCO26: Key head and neck cancer readouts from J&J, Corbus, Summit, Akero and Bicaranews2026-05-21T21:00:20+00:00May 21st, 2026|Endpoints News|
BioMarin to seek further approval of Voxzogo in form of short staturenews2026-05-21T14:31:00+00:00May 21st, 2026|Endpoints News|
The next big pharma company will come from Chinanews2026-05-20T17:44:24+00:00May 20th, 2026|Endpoints News|
Driven by GLP-1s, pharma’s relationship with consumers is starting to changenews2026-05-20T17:26:36+00:00May 20th, 2026|Endpoints News|
TrumpRx adds hundreds of generic medicines to sitenews2026-05-19T19:07:00+00:00May 19th, 2026|Endpoints News|
